Obesity, Type 2 Diabetes, Lifestyle Factors and Risk of Gallstone Disease: A Mendelian Randomization Investigation

Shuai Yuan, Dipender Gill, Edward L. Giovannucci, Susanna C. Larsson



 PII:
 S1542-3565(21)00001-X

 DOI:
 https://doi.org/10.1016/j.cgh.2020.12.034

 Reference:
 YJCGH 57675

To appear in: *Clinical Gastroenterology and Hepatology* Accepted Date: 30 December 2020

Please cite this article as: Yuan S, Gill D, Giovannucci EL, Larsson SC, Obesity, Type 2 Diabetes, Lifestyle Factors and Risk of Gallstone Disease: A Mendelian Randomization Investigation, *Clinical Gastroenterology and Hepatology* (2021), doi: https://doi.org/10.1016/j.cgh.2020.12.034.

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2021 by the AGA Institute



GWASs, Genome-wide association studies; MR, Mendelian randomization

Clinical Gastroenterology and Hepatology

Obesity, Type 2 Diabetes, Lifestyle Factors and Risk of Gallstone Disease: A Mendelian Randomization Investigation

Running head: Risk factors for gallstone disease

Shuai Yuan,¹ Dipender Gill,²⁻⁵ Edward L Giovannucci,⁶⁻⁸ Susanna C. Larsson^{1,9*}

¹Unit of Cardiovascular and Nutritional Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden

²Department of Biostatistics and Epidemiology, School of Public Health, Imperial College London, London, United Kingdom

³Clinical Pharmacology and Therapeutics Section, Institute of Medical and Biomedical Education and Institute for Infection and Immunity, St George's, University of London, London, United Kingdom ⁴Clinical Pharmacology Group, Pharmacy and Medicines Directorate, St George's University Hospitals NHS Foundation Trust, London, United Kingdom.

⁵Novo Nordisk Research Centre Oxford, Old Road Campus, Oxford, United Kingdom

⁶Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA

⁷Department of Epidemiology, Harvard T H Chan School of Public Health, Boston, MA, USA

⁸Department of Nutrition, Harvard T H Chan School of Public Health, Boston, MA, USA

⁹Unit of Medical Epidemiology, Department of Surgical Sciences, Uppsala University, Uppsala, Sweden

*Corresponding author:

Susanna C. Larsson, PhD, Associate professor Institute of Environmental Medicine, Karolinska Institutet, Nobelsväg 13, Stockholm, 17177, Sweden; Tel: <u>46-852486059</u>; E-mail: <u>susanna.larsson@ki.se</u>

Word count of abstract: 254

Word count of text: 3916 (main text 2293 words, table and figure legends 553 words, references 1070 words)

Numbers of tables: 2 / figures: 3

Abbreviations used in this paper: BMI, body mass index; CI, confidence interval; LD, linkage disequilibrium; MR, Mendelian randomization; OR, odds ratios; SD, standard deviation; SNP, single-nucleotide polymorphisms.

Disclosure / **Conflict of interest declaration:** All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: no support from any organization for the submitted work. Other conflicts of interest are listed below.

Dipender Gill is employed part-time by Novo Nordisk, outside of the submitted work.

Financial support: The study is funded by the Swedish Research Council for Health, Working Life and Welfare (Forte; grant no. 2018-00123), the Swedish Research Council (Vetenskapsrådet; grant no. 2019-00977), and the Swedish Heart-Lung Foundation (Hjärt-Lungfonden; grant no. 20190247). Dipender Gill is supported by the British Heart Foundation Research Centre of Excellence (RE/18/4/34215) at Imperial College London.

Role of the Funder: Funders had no roles in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; or the decision to submit the manuscript for publication.

Specific author contributors: Study conception and design: S.Y., D.G, E.L.G., S.C.L; data acquisition and analysis: S.Y.; drafting the manuscript and figures: S.Y.; reviewing the manuscript: S.Y., D.G, E.L.G., S.C.L.

Guarantor of the article: S.C. Larsson, PhD

Ethical approval: All studies had been approved by a relevant ethical review board and participants had given informed consent.

Transparency declaration: The lead author (the manuscript's guarantor) affirms that this manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as planned (and, if relevant, registered) have been explained.

Acknowledgements: Genetic association estimates for gallstone disease were obtained from the UK Biobank and FinnGen consortium. The authors thank all investigators for sharing these data.

Data sharing statement: The datasets analyzed in this study are publicly available summary statistics. Data used can be obtained upon a reasonable request to the corresponding author.

Abstract

Background & Aims Obesity, type 2 diabetes, and lifestyle factors (cigarette smoking, alcohol drinking, and coffee consumption) have been associated with the risk of developing gallstone disease in observational studies, but whether these associations are causal is undetermined. We conducted a Mendelian randomization study to assess these associations.

Methods Genetic instruments associated with the exposures at the genome-wide significance $(p < 5 \times 10^{-8})$ level were selected from corresponding genome-wide associations studies $(n=224\ 459\ to\ 1\ 232\ 091\ individuals)$. Summary-level data for gallstone disease were obtained from the UK Biobank (10 520 cases and 350 674 non-cases) and FinnGen consortium (11 675 cases and 121 348 non-cases). Univariable and multivariable Mendelian randomization analyses were conducted. Results from UK Biobank and FinnGen were combined using fixed-effects meta-analysis.

Results The odds ratios were 1.63 (95% confidence interval (CI), 1.49, 1.79) for one standard deviation (SD) increase in body mass index, 1.81 (95% CI, 1.60, 2.05) for one SD increase in waist circumference, 1.13 (95% CI, 1.09, 1.17) for one unit increase in the log-odds ratio of type 2 diabetes and 1.25 (95% CI, 1.16, 1.34) for one SD increase in prevalence of smoking initiation. The associations for body mass index and type 2 diabetes persisted after mutual adjustment. Genetically predicted coffee consumption was inversely associated with gallstone disease after adjustment for body mass index and smoking (odds ratio per 50% increase 0.44, 95% CI, 0.21, 0.91). There was no association with alcohol consumption.

Conclusions This study supports independent causal roles of obesity, type 2 diabetes, and smoking in gallstone disease.

Keywords: gallstones; lifestyle factors; type 2 diabetes

Background

Gallstone disease affects around 10% to 20% of the global adult population and is associated with the highest socioeconomic costs of all gastrointestinal conditions.¹⁻³ Serious complications, such as cholecystitis, cholangitis, and pancreatitis, as well as gallstone recurrence influence health status and quality of life of gallstone patients after cholecystectomy.⁴ Obesity,^{1, 2, 4} type 2 diabetes⁵⁻⁷ and cigarette smoking⁸ have been proposed as risk factors, and alcohol^{4, 9, 10} and coffee^{4, 11, 12} consumption as protective factors for gallstones in traditional observational studies. However, the causality of these observational findings cannot be determined as residual confounding may have biased the results. For example, obesity and type 2 diabetes are closely interrelated and their independent association with cholelithiasis is uncertain. Likewise, cigarette smoking, alcohol drinking, and coffee consumption are overlapping behaviors,¹³ and this may introduce residual confounding in observational studies.

Mendelian randomization (MR) leverages the random allocation of genetic variants during conception as instrumental variables to estimate the causal association between an exposure (e.g., body mass index (BMI)) and health outcome.¹⁴ Here, the MR design was used to assess the potential causal associations of overall obesity (measured as BMI), abdominal obesity (measured as waist circumference), type 2 diabetes, and lifestyle factors (cigarette smoking, alcohol drinking, and coffee consumption) with risk of gallstone disease.

Methods

Study design and data sources

Study design overview and the assumptions of a Mendelian randomization study are shown in **Figure 1.** Genetic instruments for the exposures were obtained from published genomewide association studies.¹⁵⁻¹⁹ Data for gallstone disease were obtained from UK Biobank²⁰ and the FinnGen consortium²¹. Detailed information on used data sources is displayed in **Table 1**. All studies had been approved by a relevant ethical review board and participants had given informed consent.

Genetic instrument selection

Genetic instruments for BMI¹⁵, waist circumference (with and without adjustment for BMI)¹⁶, cigarette smoking¹⁷, alcohol drinking¹⁷, coffee consumption¹⁸, and type 2 diabetes¹⁹ were selected at genome-wide significance threshold ($p < 5 \times 10^{-8}$) from corresponding genome-wide association studies. A set of genetic instruments associated with smoking index²² (taking into account smoking status as well as smoking duration, heaviness, and cessation in ever smokers) were used in a supplementary analysis. Linkage disequilibrium (LD) among single-nucleotide polymorphisms (SNPs) for each risk factor was calculated based on 1000 genomes LD reference panel (European population) using the PLINK clumping method. SNPs in LD (r^2 >0.01 and clump window <10 kb) were excluded and the SNP with the lowest *p*-value was retained. In the analysis of coffee consumption, five SNPs were excluded due to pleiotropic associations with other potential risk factors (in particular BMI) at genome-wide significance (rs1260326 in the *GCKR* gene, rs574367 in *SEC16B*, rs10865548 in *TMEM18*, rs66723169 in *MC4R*, and rs34060476 in *MLXIPL*).²³

Data sources for gallstone disease

Summary-level genetic data for gallstone disease (cholelithiasis, defined by the International Classification of Diseases 10th Revision code K80) were obtained from the UK Biobank cohort²⁰ and the FinnGen consortium²¹. The second wave of analyses of UK Biobank from Neale lab was used in the present study. Data from Neale lab included 361 194 UK Biobank participants after exclusion of individuals of non-European ancestry, closely related

individuals (or at least one of a related pair of individuals), individuals with sex chromosome aneuploidies, and individuals who had withdrawn consent from the UK Biobank study. Association tests had been adjusted for age, sex and up to 20 principal components. The R3 release of the FinnGen consortium data was used. In that dataset, individuals with ambiguous gender, high genotype missingness (>5%), excess heterozygosity (±4 standard deviation) and non-Finnish ancestry had been excluded. Association tests had been adjusted for age, sex, 10 genetic principal components and genotyping batch.

Statistical analysis

The multiplicative random-effects inverse-variance weighted model was used to obtain the MR estimates. Derived estimates based on UK Biobank and the FinnGen consortium were combined using fixed-effects meta-analysis. Multivariable random-effects inverse-variance weighted model was used to adjust for BMI in the analysis of type 2 diabetes and vice versa. We also conducted a two-step multivariable MR analysis in the analysis of coffee consumption to adjust for BMI and smoking initiation. Likewise, multivariable MR analysis was performed to adjust for smoking initiation in the analysis of alcohol drinking as these two traits are genetically correlated $(r_g=0.34)^{17}$. Three other methods, including the weighted median, MR-Egger regression and MR-PRESSO methods, were used as sensitivity analyses. The weighted median model provides consistent estimates on the condition that \geq 50% of the weight in the analysis comes from valid instrumental variables.²⁴ MR-Egger regression analysis can detect and correct for directional pleiotropy whereas it compromises power.²⁵ The p value for the MR-Egger intercept was used to indicate directional pleiotropy. The MR-PRESSO approach can detect outliers and generate estimates after outliers removing.²⁶ The MR-PRESSO distortion test aims at examining the differences between the estimates before and after outlier correction and a p < 0.05 of distortion test indicates a significant difference in

estimates before and after outlier correction.²⁶ Cochrane's Q value was estimated to assess the heterogeneity among used SNPs for each risk factor. Odds ratios (ORs) and corresponding confidence intervals (CIs) of gallstone disease were scaled to one standard deviation (SD) increase in BMI and waist circumference, one unit increase in log-odds ratio of type 2 diabetes, one SD increase in prevalence of smoking initiation, one SD increase of lifetime smoking index, one SD increase of log-transformed alcoholic drinks/week, and 50% increase in coffee consumption, respectively. All analyses were performed using the TwoSampleMR²⁷, Mendelianrandomization²⁸ and MR-PRESSO²⁶ packages in R Software 3.6.0.

Results

Genetically predicted higher BMI, waist circumference, and liability to type 2 diabetes were associated with elevated risk of gallstone disease in UK Biobank, FinnGen and meta-analysis (p<0.001) (**Figure 2 and Figure 3**). The combined ORs of gallstones were 1.63 (95% CI, 1.49, 1.79) per one SD increase in BMI, 1.81 (95% CI, 1.60, 2.05) per one SD increase in waist circumference, and 1.13 (95% CI, 1.09, 1.17) for one unit increase in log-odds ratio of type 2 diabetes. The associations were consistent in all sensitivity analyses, though pleiotropy was detected in the analysis of type 2 diabetes in UK Biobank by the MR-Egger regression. After removing outliers in the MR-PRESSO analysis, the association between type 2 diabetes and cholelithiasis persisted and the p value for the distortion test were above 0.05 (**Table 2**). Associations for BMI and type 2 diabetes persisted and attenuated slightly after mutual adjustment (**Figure 2**). The association between genetically predicted waist circumference and gallstone disease did not remain in UK Biobank, and attenuated greatly in FinnGen after adjusting for BMI (**Figure 3**).

Among lifestyle factors, genetic predisposition to smoking initiation was associated with gallstones in the meta-analysis of data from UK Biobank and FinnGen (OR 1.25; 95% CI, 1.16, 1.34, for one SD increase in smoking prevalence) (**Figure 3 and Table 2**). This positive association was replicated in the sensitivity analysis of lifetime smoking index. There were no associations of alcohol or coffee consumption with gallstones in the primary analysis (**Figure 3**) or the sensitivity analyses of each data source (**Table 2**). After adjustment for BMI, coffee consumption showed an inverse association with gallstones (OR 0.50; 95% CI, 0.29, 0.88, per 50% increase in coffee consumption). This association remained after additional adjustment for smoking initiation (OR 0.44; 95% CI, 0.21, 0.91). In meta-analysis of estimates from UK Biobank and FinnGen, coffee consumption showed an association with gallstones in analysis based on the weighted median method with OR of 0.78 (95% CI, 0.63, 0.97). Genetically predicted alcohol drinking (the combined OR 1.06; 95% CI, 0.77, 1.47) was not associated with gallstones in the multivariable MR analysis adjusting for smoking initiation.

Discussion

The present MR study supports that both obesity and type 2 diabetes are independently and causally associated with the risk of gallstone disease. Moreover, our results provide support for a causal association between smoking and risk of gallstone disease. A possible causal association is observed between high coffee consumption and decreased risk of gallstone disease. There is no evidence that alcohol drinking is causally associated with gallstones.

BMI, representing overall obesity, has been associated with gallstones in observational studies^{4, 29} and in a one-sample MR study in 77 679 Danish adults,³⁰ which was corroborated by the present two-sample MR analysis in British and Finnish populations. The association between waist circumference and gallstones did not remain after adjustment for

BMI, which indicated that central obesity is not a more important risk factor than overall fat mass for gallstone disease. The association between obesity and gallstones was slightly attenuated in the multivariable MR analysis with adjustment for genetically predicted type 2 diabetes liability, which may suggest that type 2 diabetes partly mediates this association. Several mechanisms, including alterations of metabolic factors, hepatic secretion of supersaturated bile, dyslipidemia, intestinal and gallbladder hypomotility, gallbladder stasis, decreased secretion of bile acids, cholesterol crystallization and precipitation, and supersaturated gallbladder bile, may underlie the increased risk of gallstones among obese individuals.³¹ Even though obesity plays a causal role in the development of gallstones, both bariatric and a low-calorie diet have been shown to increase the risk of asymptomatic and symptomatic gallstones.^{32, 33} Such increased risk might be related to a rapid weight loss.³⁴

Studies of the association of type 2 diabetes with risk of gallstones have not been entirely consistent. A meta-analysis of 10 cohort studies showed an overall 56% increased risk of gallstones among diabetes patients compared with individuals without diabetes⁷. An increased risk of gallstones in type 2 diabetes patients was also found in a cross-sectional study with more than 4 million diabetes patients⁶, but not in several other case-control studies^{5, 35}. In one of those case-control studies, type 2 diabetes was associated with gallstones in the univariable (crude) analysis, but the association was attenuated after adjustment for obesity and other risk factors³⁵. The present MR study based on a large number of gallstone disease cases revealed a possibly causal association between type 2 diabetes and gallstones and the association between type 2 diabetes and gallstone disease. For example, hepatic insulin resistance has been shown to directly promote the formation of cholesterol gallstones.³⁶ Gallbladder hypomotility in diabetes might be an additional predisposing factor for cholesterol gallstone formation.³

Epidemiological data on the association between cigarette smoking and gallstones are inconsistent with positive^{8, 37} and null findings³⁸ reported. Our study provided evidence to support a causal role of cigarette smoking in the development of gallstone and further that the association is likely independent of BMI. The different effect sizes of smoking on gallstones in UK Biobank and FinnGen might be related to differences in smoking patterns. Meta-analyses on alcohol consumption in relation to gallstones revealed a dose-response inverse relationship^{9, 10} and a J-shaped association (the risk of gallstones decreased with increasing alcohol consumption up to 30 g/day and thereafter plateaued)¹⁰. However, our study did not confirm the inverse association^{4, 9}, but could not rule out a possible weak non-linear association of alcohol drinking with gallstones.

With regard to coffee consumption, an inverse association with risk of overall and symptomatic gallstone disease has been found in observational studies^{4, 11, 12} and in a one-sample MR study based on 114 220 Danish individuals (including 7294 cases)³⁹. The present MR study supported a possible association between high coffee consumption and lower risk of gallstones. Potential mechanisms underlying this inverse association might be that components in coffee stimulate cholecystokinin release, enhance gallbladder motility, inhibit gallbladder fluid absorption, decrease cholesterol crystallization in bile, down-regulate the hepatic low density lipoprotein receptor and decrease 3-hydroxyl-3-methylglutaryl Co A reductase activity.⁴⁰

The major strengths of the present study are the MR design and the large number of gallstone disease cases. The similar results in two independent populations supported the robustness and reliability of our results for the associations of obesity and type 2 diabetes with gallstones. Genetic associations with the International Classification of Diseases-defined gallstone endpoint in UK Biobank has been replicated in both Icelandic and Danish cohorts,^{41, 42} which supported a high validity of gallstone definition in our study. Population

stratification bias is unlikely to have influenced our results as the majority of recruited participants in the genome-wide association studies were of European origin and adjustment was made for population structure through genetic principal components. However, this population confinement might also limit the generalizability of our findings to other populations.

A limitation of the present study is that we could not distinguish between cholesterol and pigment gallstones, which have different etiologies. Nevertheless, the vast majority of gallstones in the Western world are cholesterol gallstones.

A potential concern in any MR study is pleiotropy. There are two types of pleiotropy in MR studies – vertical and horizontal pleiotropy.^{43, 44} In this study, genetic instruments for BMI influenced the risk of gallstone disease partly via type 2 diabetes, which would represent vertical pleiotropy (or mediated pleiotropy) as BMI was a causal risk factor for type 2 diabetes.⁴⁵ Vertical pleiotropy is not a barrier in causal inference of MR studies.^{43, 44} The genetic instruments for coffee consumption had moderate correlations with BMI and smoking.¹⁸ Given that coffee consumption is less likely to cause obesity and smoking initiation, this phenomenon called horizontal pleiotropy would bias causal estimation. We found an inverse association between genetically predicted coffee consumption and gallstones after removal of pleiotropy by excluding pleiotropic genetic variants and after adjusting for BMI and smoking through multivariable MR analysis.^{43, 44} Considering the consistent associations of genetic predisposition to type 2 diabetes and smoking initiation with gallstone disease across the two data sources and different MR models, these results are unlikely to be driven by horizontal pleiotropy.

In conclusion, the present study provides MR evidence supporting causal roles of obesity, type 2 diabetes and cigarette smoking in gallstones. The possible association between coffee consumption and gallstone disease needs verification.

11

References

- 1. Lammert F, Gurusamy K, Ko CW, et al. Gallstones. Nat Rev Dis Primers. 2016;2:16024.
- 2. European Association for the Study of the Liver. EASL Clinical Practice Guidelines on the prevention, diagnosis and treatment of gallstones. J Hepatol. 2016;65(1):146-81.
- 3. Portincasa P, Moschetta A, Palasciano G. Cholesterol gallstone disease. Lancet. 2006;368(9531):230-9.
- 4. Wirth J, Joshi AD, Song M, et al. A healthy lifestyle pattern and the risk of symptomatic gallstone disease: results from 2 prospective cohort studies. Am J Clin Nutr. 2020;112(3):586-594.
- 5. Bodmer M, Brauchli YB, Jick SS, et al. Diabetes mellitus and the risk of cholecystectomy. Dig Liver Dis. 2011;43(9):742-7.
- 6. Ali AK, Adetunji OR. Incidence and Prevalence of Bile Duct and Gallbladder Disease in Patients with Diabetes in the U.S. Diabetes. 2018;67 (Supplement 1):1559-P.
- 7. Aune D, Vatten LJ. Diabetes mellitus and the risk of gallbladder disease: A systematic review and meta-analysis of prospective studies. J Diabetes Complications. 2016;30(2):368-73.
- 8. Aune D, Vatten LJ, Boffetta P. Tobacco smoking and the risk of gallbladder disease. Eur J Epidemiol. 2016;31(7):643-53.
- 9. Wang J, Duan X, Li B, et al. Alcohol consumption and risk of gallstone disease: a meta-analysis. Eur J Gastroenterol Hepatol. 2017;29(4):e19-e28.
- 10. Cha BH, Jang MJ, Lee SH. Alcohol Consumption Can Reduce the Risk of Gallstone Disease: A Systematic Review with a Dose-Response Meta-Analysis of Case-Control and Cohort Studies. Gut Liver. 2019;13(1):114-31.
- 11. Zhang YP, Li WQ, Sun YL, et al. Systematic review with meta-analysis: coffee consumption and the risk of gallstone disease. Aliment Pharmacol Ther. 2015;42(6):637-48.
- Leitzmann MF, Stampfer MJ, Willett WC, et al. Coffee intake is associated with lower risk of symptomatic gallstone disease in women. Gastroenterology. 2002;123(6):1823-30.
- 13. Carmody TP, Brischetto CS, Matarazzo JD, et al. Co-occurrent use of cigarettes, alcohol, and coffee in healthy, community-living men and women. Health Psychol. 1985;4(4):323-35.
- 14. Burgess S, Thompson SG. Mendelian randomization: methods for using genetic variants in causal estimation: CRC Press; 2015.
- 15. Locke AE, Kahali B, Berndt SI, et al. Genetic studies of body mass index yield new insights for obesity biology. Nature. 2015;518(7538):197-206.
- 16. Shungin D, Winkler TW, Croteau-Chonka DC, et al. New genetic loci link adipose and insulin biology to body fat distribution. Nature. 2015;518(7538):187-96.
- 17. Liu M, Jiang Y, Wedow R, et al. Association studies of up to 1.2 million individuals yield new insights into the genetic etiology of tobacco and alcohol use. Nat Genet. 2019;51(2):237-44.
- 18. Zhong VW, Kuang A, Danning RD, et al. A genome-wide association study of bitter and sweet beverage consumption. Hum Mol Genet. 2019;28(14):2449-57.
- 19. Vujkovic M, Keaton JM, Lynch JA, et al. Discovery of 318 new risk loci for type 2 diabetes and related vascular outcomes among 1.4 million participants in a multi-ancestry meta-analysis. Nat Genet. 2020;52(7):680-91.

- 20. Sudlow C, Gallacher J, Allen N, et al. UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age. PLoS Med. 2015;12(3):e1001779.
- 21. The FinnGen consortium. FinnGen documentation of R3 release, 2020. (Available from) https://finngen.gitbook.io/documentation/. Data accessed: July 28, 2020.
- 22. Wootton RE, Richmond RC, Stuijfzand BG, et al. Evidence for causal effects of lifetime smoking on risk for depression and schizophrenia: a Mendelian randomisation study. Psychol Med. 2019;50(14):2435-2443.
- 23. Yuan S, Larsson SC. No association between coffee consumption and risk of atrial fibrillation: A Mendelian randomization study. Nutr Metab Cardiovasc Dis. 2019;29(11):1185-8.
- 24. Bowden J, Davey Smith G, Haycock PC, et al. Consistent Estimation in Mendelian Randomization with Some Invalid Instruments Using a Weighted Median Estimator. Genet Epidemiol. 2016;40(4):304-14.
- 25. Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression. Int J Epidemiol. 2015;44(2):512-25.
- 26. Verbanck M, Chen CY, Neale B, et al. Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases. Nat Genet. 2018;50(5):693-8.
- 27. Hemani G, Zheng J, Elsworth B, et al. The MR-Base platform supports systematic causal inference across the human phenome. Elife. 2018;7:e34408.
- 28. Yavorska OO, Burgess S. MendelianRandomization: an R package for performing Mendelian randomization analyses using summarized data. Int J Epidemiol. 2017;46(6):1734-9.
- 29. Bonfrate L, Wang DQ, Garruti G, et al. Obesity and the risk and prognosis of gallstone disease and pancreatitis. Best Pract Res Clin Gastroenterol. 2014;28(4):623-35.
- 30. Stender S, Nordestgaard BG, Tybjaerg-Hansen A. Elevated body mass index as a causal risk factor for symptomatic gallstone disease: a Mendelian randomization study. Hepatology. 2013;58(6):2133-41.
- Cruz-Monserrate Z, Conwell DL, Krishna SG. The Impact of Obesity on Gallstone Disease, Acute Pancreatitis, and Pancreatic Cancer. Gastroenterol Clin North Am. 2016;45(4):625-37.
- 32. Everhart JE. Contributions of obesity and weight loss to gallstone disease. Ann Intern Med. 1993;119(10):1029-35.
- 33. Jonas E, Marsk R, Rasmussen F, et al. Incidence of postoperative gallstone disease after antiobesity surgery: population-based study from Sweden. Surg Obes Relat Dis. 2010;6(1):54-8.
- 34. Weinsier RL, Ullmann DO. Gallstone formation and weight loss. Obes Res. 1993;1(1):51-6.
- 35. Pacchioni M, Nicoletti C, Caminiti M, et al. Association of obesity and type II diabetes mellitus as a risk factor for gallstones. Dig Dis Sci. 2000;45(10):2002-6.
- 36. Biddinger SB, Haas JT, Yu BB, et al. Hepatic insulin resistance directly promotes formation of cholesterol gallstones. Nat Med. 2008;14(7):778-82.
- 37. Jørgensen T. Gall stones in a Danish population. Relation to weight, physical activity, smoking, coffee consumption, and diabetes mellitus. Gut. 1989;30(4):528-34.
- 38. Friedrich N, Völzke H, Hampe J, et al. Known risk factors do not explain disparities in gallstone prevalence between Denmark and northeast Germany. Am J Gastroenterol. 2009;104(1):89-95.

- 39. Nordestgaard AT, Stender S, Nordestgaard BG, et al. Coffee intake protects against symptomatic gallstone disease in the general population: a Mendelian randomization study. J Intern Med. 2020;287(1):42-53.
- 40. Cuevas A, Miquel JF, Reyes MS, et al. Diet as a risk factor for cholesterol gallstone disease. J Am Coll Nutr. 2004;23(3):187-96.
- 41. Ferkingstad E, Oddsson A, Gretarsdottir S, et al. Genome-wide association metaanalysis yields 20 loci associated with gallstone disease. Nat Commun. 2018;9(1):5101.
- 42. Gellert-Kristensen H, Dalila N, Fallgaard Nielsen S, et al. Identification and Replication of Six Loci Associated With Gallstone Disease. Hepatology. 2019;70(2):597-609.
- 43. Davies NM, Holmes MV, Davey Smith G. Reading Mendelian randomisation studies: a guide, glossary, and checklist for clinicians. Bmj. 2018;362:k601.
- 44. Holmes MV, Ala-Korpela M, Smith GD. Mendelian randomization in cardiometabolic disease: challenges in evaluating causality. Nat Rev Cardiol. 2017;14(10):577-90.
- 45. Wainberg M, Mahajan A, Kundaje A, et al. Homogeneity in the association of body mass index with type 2 diabetes across the UK Biobank: A Mendelian randomization study. PLoS Med. 2019;16(12):e1002982.

ournalpre

Figure legends

Figure 1. Study design overview and assumptions of the Mendelian randomization design. BMI, body mass index; IVW, inverse-variance weighted; LD, linkage disequilibrium; SNP, single-nucleotide polymorphisms; T2DM, type 2 diabetes mellitus; WC, waist circumference. Assumption 1 indicates that the genetic variants proposed as instrumental variables should be robustly associated with the risk factor of interest; assumption 2 indicates that the used genetic variants should not be associated with potential confounders, and assumption 3 indicates that the selected genetic variants should affect the risk of the outcome merely through the risk factor, not via alternative pathways. The Mendelian randomization design can reduce residual confounding and reverse causality, thereby reinforcing the causal inference of an exposure-outcome association. The basis of this is that genetic variants, selected as instrumental variable for studying the effect of modifying the exposure, are randomly allocated at conception and are therefore less vulnerable to confounding from environmental factors and reverse causation.

Figure 2. Associations of body mass index and type 2 diabetes with gallstone disease in univariable and multivariable Mendelian randomization analyses. CI, confidence interval; IVW, inverse-variance weighted; OR, odds ratio; UKBB, UK Biobank. The multivariable MR analysis adjusted for type 2 diabetes in the analysis of body mass index and vice versa. The ORs of gallstone disease were scaled to one standard deviation increase in body mass index and one unit increase in log-odds ratio of type 2 diabetes.

Figure 3. Associations of genetically predicted waist circumference and modifiable lifestyle factors with gallstone disease*. BMI indicates body mass index; CI, confidence interval; OR, odds ratio; UKBB, UK Biobank. Estimates for coffee consumption with adjustment for BMI were derived from the multivariable inverse-variance weighted model with random effects. The ORs of gallstone disease were scaled to one standard deviation increase in waist circumference, one standard deviation increase in prevalence of smoking initiation, one standard deviation increase of lifetime smoking index, one standard deviation increase of logtransformed alcoholic drinks/week and 50% increase in coffee consumption. *Estimates were derived using the multiplicative random-effects inverse-variance weighted Mendelian randomization method and combined using fixed-effects meta-analysis.

Exposure or outcome	Unit	Participants included in analysis	Adjustments	Identified SNPs	PubMed ID or web-link
BMI	SD	339 224 individuals of multi- ancestries	Age and any necessary study- specific covariates	97	25673413
Waist circumference	SD	224 459 individuals of European ancestry	Age and study-specific covariates	47	25673412
Waist circumference adjusted for BMI	SD	224 459 individuals of European ancestry	Age, body mass index and study- specific covariates	70	25673412
Type 2 diabetes	One-unit in log- odds ratio of type 2 diabetes	228 499 type 2 diabetes cases and 1 178 783 non-cases of multi-ancestries	Age, sex, and the first ten genetic principal components	558	32541925
Smoking initiation	SD in prevalence of smoking initiation	1 232 091 European-descent individuals	Age, sex, and the first ten genetic principal components	378	30643251
Lifetime smoking index	SD change of lifetime smoking index	462 690 European-descent individuals	Genotyping chip and sex	126	31689377
Alcohol drinking	SD increase of log-transformed alcoholic drinks/week	941 280 European-descent individuals	Age, sex, and the first ten genetic principal components	99	30643251
Coffee consumption	50% change	375 833 European-descent individuals	Age, sex, body mass index, total energy, proportion of typical food intake and 20 genetic principal components	14	31046077
Gallstone disease*	-	10 520 gallstone disease cases and 350 674 non-cases	Age, sex and up to 20 genetic principal components	-	UK Biobank (<u>http://www.nealelab.is/uk-</u> biobank)
Gallstone disease*	-	11 675 gallstone disease cases and 121 348 non-cases	Age, sex, 10 genetic principal components and genotyping batch	-	FinnGen consortium (<u>https://www.finngen.fi/fi</u>)

BMI indicates body mass index; SD, standard deviation; SNPs, single-nucleotide polymorphism. *Defined by the International Classification of Diseases 10th Revision code K80. Unit for coffee consumption was rescaled to 50% increase based on 1% increase reported in genome-wide association study.

	Used	Cochrane's		Weighted m	edian		MR-Egge	r		MR-PRES	SSO	D a	D b
	SNPs	Q	OR	95% CI	Р	OR	95% CI	Р	OR	95% CI	Р	- P _{pleiotropy} ^a	P _{distortion test} ^D
UK Biobank													
BMI	93	91.79	1.53	1.26, 1.85	1.75×10^{-5}	1.50	1.12, 2.00	0.008	1.61	1.43, 1.81	5.52×10^{-12}	0.591	0.554
Waist circumference	45	45.69	1.48	1.15, 1.91	0.003	1.74	1.14, 2.68	0.015	1.64	1.40, 1.92	2.42×10^{-7}	0.763	0.433
Waist circumference	70	105.77	1.06	0.86, 1.31	0.579	1.16	0.56, 2.39	0.687	0.99	0.84, 1.18	0.937	0.003	0.665
adjusted for BMI													
Type 2 diabetes	488	707.89	1.10	1.04, 1.17	0.001	1.02	0.94, 1.11	0.592	1.12	1.08, 1.17	2.47×10^{-8}	0.009	0.709
Smoking initiation	309	406.80	1.30	1.14, 1.48	7.60×10 ⁻⁵	1.10	0.72, 1.69	0.666	1.39	1.25, 1.54	9.10×10 ⁻¹⁰	0.253	0.841
Lifetime smoking index	126	164.77	1.58	1.20, 2.07	0.001	0.62	0.28, 1.39	0.251	1.56	1.28, 1.89	1.85×10^{-5}	0.016	0.569
Alcohol drinking	82	240.89	1.00	0.60, 1.65	0.995	1.09	0.45, 2.68	0.848	1.07	0.79, 1.46	0.654	0.662	0.050
Coffee consumption	9	27.10	0.81	0.57, 1.15	0.248	0.76	0.37, 1.58	0.488	0.99	0.77, 1.28	0.953	0.829	< 0.001
FinnGen													
BMI	93	122.80	1.74	1.40, 2.18	1.06×10^{-6}	2.09	1.45, 3.01	1.63×10 ⁻⁴	1.62	1.40, 1.87	4.86×10 ⁻⁹	0.189	0.730
Waist circumference	45	66.74	2.27	1.76, 2.93	3.44×10^{-10}	3.08	1.79, 5.30	2.13×10 ⁻⁴	2.05	1.69, 2.48	5.60×10 ⁻⁹	0.163	0.662
Waist circumference	70	116.12	1.31	1.03, 1.65	0.027	0.70	0.30, 1.63	0.420	1.23	1.01, 1.49	0.037	< 0.001	0.188
adjusted for BMI													
Type 2 diabetes	468	761.75	1.10	1.03, 1.18	0.008	1.11	1.00, 1.22	0.044	1.12	1.07, 1.17	1.40×10^{-6}	0.636	0.620
Smoking initiation	295	333.40	1.11	0.96, 1.29	0.160	0.83	0.53, 1.30	0.414	1.09	0.98, 1.22	0.100	0.214	NA
Lifetime smoking index	124	178.11	1.14	0.84, 1.55	0.411	0.29	0.11, 0.77	0.015	1.23	0.97, 1.57	0.096	0.004	NA
Alcohol drinking	78	193.20	0.97	0.57, 1.65	0.918	0.60	0.17, 2.13	0.434	0.87	0.59, 1.26	0.459	0.697	0.754
Coffee consumption	9	16.86	0.77	0.59, 1.02	0.066	0.78	0.39, 1.54	0.495	0.82	0.66, 1.02	0.118	0.697	0.620

Table 2. Associations of genetically predicted risk factors with gallstone disease in Mendelian randomization sensitivity analyses

BMI, indicates body mass index; CI, confidence interval; NA, not available; OR, odds ratio; SNPs, single-nucleotide polymorphisms. The ORs of gallstone disease were scaled to one standard deviation increase in BMI and waist circumference, one unit increase in log-odds ratio of type 2 diabetes, one standard deviation increase of smoking initiation, one standard deviation increase of lifetime smoking index, one standard deviation increase of log-transformed alcoholic drinks/week and 50% increase in coffee consumption.

^a*P* values for pleiotropy were derived from MR-Egger test and a *p* value < 0.05 indicates a possible pleiotropic effect.

^b*P* values for distortion were derived from MR-PRESSO test and a *p* value < 0.05 indicates a difference between estimates before and after outlier removal. *P* of distortion test was not available for the analysis of smoking initiation and lifetime smoking index based on FinnGen consortium due to no outlier detected.



FinnGen 1.67 (1.43, 1.94) 2.8×10 ⁻¹ Combined effect 1.63 (1.49, 1.79) <0.001 Estimate from multivariable IVW model 1.54 (1.35, 1.76) 0.001 UKBB 1.54 (1.35, 1.76) 0.001 FinnGen 1.61 (1.35, 1.91) 1.3×10 ⁻⁴ Combined effect 1.57 (1.41, 1.74) <0.001 Type 2 diabetes 1.13 (1.08, 1.18) 7.7×10 Estimate from univariable IVW model 1.13 (1.08, 1.18) 9.8×10 Combined effect 1.13 (1.09, 1.17) <0.001 Estimate from multivariable IVW model 1.08 (1.03, 1.12) 4.0×10 UKBB 1.08 (1.03, 1.14) 0.001	MR method & Data source	OR (95% CI)	Р
UKBB FinnGen Combined effect Estimate from multivariable IVW model UKBB FinnGen Combined effect 1.54 (1.35, 1.76) UKBB FinnGen Combined effect 1.54 (1.35, 1.76) 1.54 (1.35, 1.76) 1.54 (1.35, 1.76) 1.57 (1.41, 1.74) 0.001 1.57 (1.41, 1.74) 0.001 1.57 (1.41, 1.74) 0.001 1.57 (1.41, 1.74) 1.5 2.0 Type 2 diabetes Estimate from univariable IVW model UKBB FinnGen Combined effect Estimate from multivariable IVW model Estimate from multivariable IVW model	Body mass index		
FinnGen 1.67 (1.43, 1.94) 2.8×10 ⁻¹ Combined effect 1.63 (1.49, 1.79) <0.001	Estimate from univariable IVW model		
Combined effect 	UKBB	———— 1.61 (1.43, 1.81)	2.6×10 ⁻¹⁵
Estimate from multivariable IVW model UKBB FinnGen Combined effect Type 2 diabetes Estimate from univariable IVW model UKBB FinnGen Combined effect Estimate from multivariable IVW model Estimate from multivariable IVW model	FinnGen	——— 1.67 (1.43, 1.94)	2.8×10 ⁻¹¹
UKBB FinnGen Combined effect Type 2 diabetes Estimate from univariable IVW model UKBB FinnGen Combined effect Estimate from multivariable IVW model	Combined effect	1.63 (1.49, 1.79)	<0.001
FinnGen 1.61 (1.35, 1.91) 1.3×10 ⁻⁴ Combined effect 1.57 (1.41, 1.74) <0.001	Estimate from multivariable IVW model		
Combined effect 1.57 (1.41, 1.74) <0.001	UKBB	——— 1.54 (1.35, 1.76)	0.001
Type 2 diabetes Estimate from univariable IVW model UKBB FinnGen Combined effect Estimate from multivariable IVW model	FinnGen	———— 1.61 (1.35, 1.91)	1.3×10-4
Type 2 diabetes Estimate from univariable IVW model UKBB FinnGen Combined effect Estimate from multivariable IVW model Estimate from multivariable IVW model	Combined effect	1.57 (1.41, 1.74)	<0.001
Type 2 diabetes Estimate from univariable IVW model UKBB FinnGen Combined effect Estimate from multivariable IVW model Estimate from multivariable IVW model			
Estimate from univariable IVW model UKBB FinnGen Combined effect Estimate from multivariable IVW model Estimate from multivariable IVW model		1.5 2.0	
FinnGen 1.13 (1.08, 1.18) 9.8×10 Combined effect 1.13 (1.09, 1.17) <0.001	Type 2 diabetes		
UKBB 1.13 (1.08, 1.18) 7.7×10 ⁻¹ FinnGen 1.13 (1.08, 1.18) 9.8×10 ⁻¹ Combined effect 1.13 (1.09, 1.17) <0.001	Estimate from univariable IVW model		
FinnGen 1.13 (1.08, 1.18) 9.8×10 Combined effect 1.13 (1.09, 1.17) <0.001		1.13 (1.08, 1.18)	7.7×10 ⁻⁹
Combined effect Estimate from multivariable IVW model \sim 1.13 (1.09, 1.17) <0.001			9.8×10 ⁻⁷
	Estimate from multiveriable 11/11/ model		
FinnGen 1.08 (1.03, 1.12) 4.0x10 Combined effect 1.08 (1.03, 1.14) 0.001 <		1 00 (1 00 1 10)	1 0~10-4
Combined effect 1.08 (1.03, 1.14) 0.001 <			
		1.08 (1.05, 1.11)	<u><u></u> <u></u> <u></u> <u></u> <u></u> <u></u> <u></u> <u></u> <u></u> <u></u> </u>

OR (95% CI) of cholelithiasis

Risk factor & Data source	Journal Pre-proof	∪ห (ษ๖% CI)	Р
Waist circumference UKBB FinnGen Combined effect	- 	1.64 (1.40, 1.92) 2.14 (1.74, 2.62) 1.81 (1.60, 2.05)	1.1×10 ⁻⁹ 4.6×10 ⁻¹³ <0.001
Waist circumference adjusted for BMI UKBB FinnGen Combined effect		0.99 (0.84, 1.18) 1.23 (1.01, 1.50) 1.09 (0.96, 1.24)	0.937 0.037 0.189
Smoking initiation UKBB FinnGen Combined effect	→	1.40 (1.27, 1.55) 1.09 (0.98, 1.22) 1.25 (1.16, 1.34)	1.1×10 ⁻¹⁰ 0.098 <0.001
Lifetime smoking index UKBB FinnGen Combined effect		1.64 (1.33, 2.02) 1.23 (0.97, 1.57) 1.45 (1.24, 1.70)	3.1×10⁻⁵ 0.094 <0.001
Alcohol drinking UKBB - FinnGen - Subtotal -		1.30 (0.82, 2.06) 0.97 (0.58, 1.63) 1.14 (0.81, 1.61)	0.267 0.906 0.454
Coffee consumption UKBB FinnGen Subtotal		0.82 (0.57, 1.17) 0.88 (0.64, 1.22) 0.85 (0.67, 1.08)	0.274 0.438 0.190
Coffee consumption adjusted for BMI UKBB FinnGen Subtotal	-	0.66 (0.29, 1.53) 0.40 (0.19, 0.85) 0.50 (0.29, 0.88)	0.333 0.017 0.015
Coffee consumption adjusted for BMI & smokin UKBB FinnGen Subtotal	ng -	0.38 (0.15, 0.98) 0.53 (0.16, 1.74) 0.44 (0.21, 0.91)	0.045 0.298 0.026
0.5	1 2.0		

OR (95% CI) of gallstone disease

What You Need To Know

Background

Obesity, type 2 diabetes, and lifestyle factors have been associated with the risk of developing gallstone disease in observational studies, but whether these associations are causal is undetermined.

Findings

Genetic predisposition to obesity, type 2 diabetes and smoking initiation was associated with an increased risk of gallstone disease. Genetically predicted coffee consumption but not alcohol consumption was associated with a reduced risk of gallstone disease.

Implications for patient care

Preventing obesity and diabetes and modifying lifestyle factors may act as prevention strategies for gallstone disease.

Jonution